Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
12:01pm, Thursday, 06'th May 2021
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline.
Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech
06:10am, Thursday, 06'th May 2021
The company's revenue soared in Q1, but its bottom line still looked ugly.
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
12:00am, Thursday, 06'th May 2021
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
07:56pm, Wednesday, 05'th May 2021
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -4.48% and 4.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 05'th May 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04:30pm, Tuesday, 04'th May 2021
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will par
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 a
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
04:05pm, Monday, 26'th Apr 2021
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital I
Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas
04:40pm, Tuesday, 20'th Apr 2021
Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important up
Is Sarepta Therapeutics Worthy of Redemption?
10:39am, Thursday, 01'st Apr 2021
A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.
Edgewise Therapeutics Proposes Terms For $150 Million IPO
05:48pm, Tuesday, 23'rd Mar 2021
Edgewise Therapeutics has filed to raise $150 million in an IPO.
Can Sarepta's 'Remarkable' Gene Therapy Pull Shares Out Of The Dumps?
12:03pm, Friday, 19'th Mar 2021
An experimental gene therapy from Sarepta Therapeutics showed "remarkable" stability at two years in muscular dystrophy patients, an analyst said Friday as SRPT stock edged higher. The post Can Sarept
Sarepta Stock Has Been Battered. Positive Gene Therapy Data Sends Shares 5% Higher.
08:26am, Friday, 19'th Mar 2021
The gene therapy, known as SRP-9003, treats a disorder called limb-girdle muscular dystrophy type 2E.
-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measure
